Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
The Medicines Company |
---|---|
Information provided by: | The Medicines Company |
ClinicalTrials.gov Identifier: | NCT00093886 |
The purpose of this study is to establish the safety of clevidipine in the treatment of preoperative hypertension.
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: Clevidipine |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety Study |
Official Title: | Evaluation of Clevidipine in the Preoperative Treatment of Hypertension Assessing Safety Events (With Nitroglycerin as Active Comparator) (ECLIPSE-NTG) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Prerandomization Inclusion Criteria:
Prerandomization Exclusion Criteria:
Postrandomization Inclusion Criteria:
Study Director: | Malcolm Lloyd, MD | The Medicines Company - Medical Director, Clinical Operations |
Study ID Numbers: | TMC-CLV-03-03, ECLIPSE-NTG |
Study First Received: | October 7, 2004 |
Last Updated: | October 29, 2008 |
ClinicalTrials.gov Identifier: | NCT00093886 |
Health Authority: | United States: Food and Drug Administration |
Preoperative hypertension |
Nitroglycerin Vascular Diseases Hypertension |
Cardiovascular Diseases |